Development dynamics

From the beginning Lancet cooperates with the world leaders of the medical industry and leading domestic pharmaceutical manufacturers. We continuously work for our progress and offer new solutions to meet the trends of international and Russian healthcare.
19,1
BLN RUR

2016

Pulmonology portfolio is created as a new priority area.
Lancet strengthen its market positions in Cardiology and Medical Visualization markets.
New long-term strategy is crafted with a strategic vision to become a top-priority partner in EEU budget market.

Lancet employs more than 380 people including 102 in the Sales and Business Development departments
15,3
BLN RUR

2015

New warehouse is opened in Moscow Region.
Lancet and ChemRar: partnership in for research, development and commercialization of new medicines in Russia to stimulate the innovative development of the Russian pharmaceutical industry
36th rank in RBC ranking Growth champions. Top-50 fast growing companies in Russia (2011 2014) and 1 of 13 companies maintaining their presence in RBC ranking for the second year in a row

336 employees are working in the company
11,3
BLN RUR

2014

Creating Business Unit responsible for Interventional Surgery.
Futher development in Oncology, Obstetrics and Surgery&ICU areas.
Lancet is included in RBC top-30: Growth champions rating for the first time, being on 26th place among companies of various sectors of economy.

More than 270 employees are working in the company
8,65
BLN RUR

2013

The line of devices for interventional surgery is formed.
Cancer and Midwifery directions are being developed.
The company is awarded the 7th place in the annual Cursor ranking Successful bidders (all-Russia medical preparations tender purchases ranking).
The company opens a branch in Novosibirsk.

215 employees are working in the company
5,85
BLN RUR

2012

The special unit responsible for non-standard projects including complex multistage logistics (e.g., peritoneal dialysis) is created.
The Business Development Department is established. BDD is responsible for expanding Lancet portfolio, market launch of new products, and development of new areas of the company.
The business actively expands in the area of Obstetrics and Gynecology, gains a leading position in the segments of CT, MRI and angiography and Interventional Cardiology, Cardiac Surgery and Cardiac ICU.
The company is awarded the 10th place in the annual Cursor ranking Successful bidders (all-Russia medical preparations tender purchases ranking).
The company opens a branch in St.Petersburg.

185 employees are working in the company
3,1
BLN RUR

2011

The portfolio of Diagnostics and treatment of cardiovascular diseases is expanded through the development of partnerships with the manufacturers of devices for angioplasty and stenting.
The company is awarded the 16th place in the annual Cursor ranking Successful bidders (all-Russia medical preparations tender purchases ranking).
The company gains the 21st place in the ranking The Fastest Growing Mid-Sized Companies, 2007-2011 by Expert magazine and the 1st place among the pharmaceutical companies.
The company is present in all the territory of the Russian Federation.

110 employees are working in the company
1,75
BLN RUR

2010

The business develops in the oncology segment, the companys strengthens its position in interventional radiology and cardiology.
Lancet is awarded the 50th place in the annual Cursor ranking Successful bidders (all-Russia medical preparations tender purchases ranking).
The company is expanding its presence to the Northwestern Federal District.

84 employees are working in the company
0.72
BLN RUR

2009

A strategic partnership with the world leading manufacturers of equipment for interventional radiology and cardiology is strengthening.
Medical equipment and devices subdivision is established.
The company is expanding its presence to the Volga Federal District, Southern Federal District and Ural Federal District.

48 employees are working in the company
0,19
BLN RUR

2008

A license for pharmaceutical activity is obtained.
Diagnostics and treatment of acute coronary syndrome (ACS) is selected as a priority.
The company is present in Moscow and Moscow region, the Central Federal District, Siberian Federal District.

19 employees are working in the company